<?php require 'php-templates/header.php' ?>

<div class="wrapper pept-banner-section">
	<div class="container banner-content">
		<img src="oncopept/img/bg/banner-bg.jpg" class="img-responsive banner">
		<div class="blocks">
			<h2>OncoPept<sup><i>TM</i></sup> is a powerful end-to-end genomics platform to accelerate
			 your immuno-oncology research
			</h2>
			<p>MedGenome is the only Next Generation Sequencing (NGS) service provider offering immuno-oncology researchers an enduring, 
			science-driven partnership to deliver quicker, more affordable, customized solutions to achieve superior 
			therapeutic impact of checkpoint control inhibitors 
			and cancer vaccines through its cancer immunotherapy genomics
			 atform,OncoPept<sup><i>TM</i></sup>.
			</p>
		</div>
	</div>
</div>
<div class="wrapper">
	<div class="container pept-solution pad-space">
		<h2>OncoPept<sup><i>TM</i></sup><span>Solution</span></h2>
		<h4>OncoPept<sup><i>TM</i></sup> can be customized to meet specific research needs</h4>
		<div class="solution-block">
			<div class="block1">Provides immune phenotyping of the tumor
			 microenvironment andanalyses potential biomarkers of 
			response to enable success of checkpoint inhibitors.</div>
			<div class="block2">Delivers candidate vaccines from tumor mutanome 
			using state-of-the-art
			prediction of HLA-types,
			antigen processing and
			MHC-peptide binding.</div>
			<div class="block3">NGS based TCR
			repertoire analysis for
			differential diagnosis of
			T-cell related pathology.</div>
			<div class="block4">Provides molecular rational to combine 
			therapies developed in the 
			immuno- oncology space
			</div>
		</div>
	</div>
</div>
<div class="wrapper">
	<div class="container pept-note">
		<p>OncoPeptTOPE<sup><i>TM</i></sup>: A database of neo-antigens and neo-epitopes derived from genetic alterations 
available in TCGA data. Open access available at http://oncotope.medgenome.com</p>
	</div>
</div>
<div class="wrapper">
	<div class="container benefit-block ">
		<div class="block row clearfix">
			<table>
				<tr>
					<th>Benefits</th>
					<th></th>
					<th>Value for the customer</th>
				</tr>
				<tr>
					<td>Science driven</td>
					<td><span class="round"></span>
					<td>Incorporates latest research insights to allow clients use their 
					time more efficiently and focus on their core research activities.</td>
				</tr>
				<tr>
					<td>Customized solutions</td>
					<td><span class="round"></span>
					<td>Allow seamless integration with clients ongoing research and caters to their
					 specific preclinical and clinical research needs.</td>
				</tr>
				<tr>
					<td>Quicker TAT at an affordable cost</td>
					<td><span class="round"></span>
					<td>Robust and validated pipelines enable clients to complete their research in a
					 shorter timeframe while minimizing the overall cost.</td>
				</tr>
				<tr>
					<td>Partnership</td>
					<td><span class="round"></span>
					<td>Supports clients need in creating presentation materials, 
					figures for manuscripts and summary reports.</td>
				</tr>
				<tr>
					<td colspan="3">
						<span class="arrow"></span>Accelerate your immuno-oncology research using OncoPept<sup>TM<sup></td>
				</tr>
			</table>
		</div>
	</div>
</div>
<div class="wrapper">
	<div class="container pept-tume">
		<h2>OncoPept<i>TUME <sup>TM</sup></i></h2>
		<p>Provides immune phenotyping of the tumor microenvironment and analyses potenial
		 biomarkers of response to enable success of checkpoint inhibitors.</p>
	</div>
</div>
<div class="wrapper">
	<div class="container key-block">
		<div class="col-xs-12">
			<h4 class="pad-l60 pb-30">Key benefits</h4>
			<div class="block1">
				<P>Enables patient stratification for single agent or combination therapies</P>
			</div>
			<div class="block2">
				<P>Enhances therapeutic benefit of checkpoint control inhibitors</P>
			</div>
			<div class="block3">
				<P>Increases durability of response and patient outcome 
				and aids in predicting adverse reaction to the drug</P>
			</div>
		</div>
		<div class="col-xs-12 pl-60">
			<h4>Biomarkers of response</h4>
			<img src="oncopept/img/place-holders/graph.jpg">
		</div>
		<div class="next-arrw"></div>
	</div>
</div>
<div class="wrapper">
	<div class="container download-block">
		<a class="download">
		<h2><span class="down"></span>Download the <span>OncoPept<i>TUME<sup>TM</i></sup> 
		 </span>   product brochure</h2>
		 </a>
	</div>
</div>
<div class="wrapper">
	<div class="container vac-block pad-space">
		<h2>OncoPept<i>VAC<sup>TM</sup></i></h2>
		<p>Delivers prioritized T-cell neo-epitopes, that can be used as
		 DNA or peptide vaccine for cancer immunotherapy</p>
		 <h4>Benefits</h4>
		 <table>
		 	<tr>
		 		<th>DNA / Peptide Vaccine Composition</th>
		 		<th>DNA / Peptide Vaccine Structure</th>
		 		<th>DNA / Peptide Vaccine Validation</th>
		 	</tr>
		 	<tr>
		 		<td>Identify cancer variants with high specificity and sensitivity</td>
		 		<td>Create optimum length of the peptide or DNA vaccine</td>
		 		<td>Assay to determine efficient presentation of peptides 
		 		by antigen presenting cells, such as dendritic cells</td>
		 	</tr>
		 	<tr>
		 		<td>Identify cancer mutations that are
		 		 potentially HLA-binding and T-cell binding</td>
		 		 <td>Ensure that the peptide/DNA vaccines are processed 
		 		 correctly to produce HLA-binding neo-epitope</td>
		 		 <td>Ensure that the predicted peptide can activate T-cells</td>
		 	</tr>
		 </table>
	</div>
</div>
<div class="wrapper">
	<div class="container noval-block pad-space">
		<div class="col-xs-12 p-t10 ">
			<h4>Novel therapeutics</h4>
			<h3>Selecting cancer vaccines from somatic mutations</h3>
			<h2>OncoPept<i>VAC<sup>TM</sup></i><span> uses multiple filters to eliminate greater 
			than 99% of neo-antigens to select true T-cell neo-epitopes</span></h2>
			<a class="download clearfix">
				<div class="col-xs-4"><span class="down"></span></div>
				<div class="col-xs-20"><h2>Download the <span>OncoPept<i>VAC<sup>TM</sup></i> 
			 	</span>   product brochure</h2>
			 	</div>
			 </a>
	
		</div>
		<div class="col-xs-12 chart">
			<p>>2-log enrichment in neo-epitope prioritization </p>
			<div class="chart-block">
				<ul>
					<li>1880    All variants</li>
					<li>412     Passed variants</li>
					<li>128     Expressed variants</li>
					<li>53     HLA binding (<500nM)</li>
				</ul>
				<ul class="halfs">
					<li><span>26</span> HLA-binding neo-epitope</li>
					<li>15 Processing</li>
					<li>12 Tap binding</li>
				</ul>
				<ul class="halfs right">
					<li><span>27</span> TCR-binding neo-epitope</li>
					<li>16 Processing</li>
					<li>8 Tap binding</li>
				</ul>
			</div>
		</div>
		<div class="next-arrw"></div>
	</div>
</div>
<div class="wrapper">
	<div class="container tope-block pad-space">
		<h2>OncoPept<i>TOPE <sup>TM</sup></i></h2>
		<p>Database of neo-antigens and neo-epitopes
		 derived from genetic alterations using TCGA data</p>
		 <a class="block">
		 	<div class="block-cnt">
		 		<h4>Click here to get <span>free access</span> </h4>
		 		<h2><span>to the </span>OncoPept<i>TOPE <sup>TM</sup></i></h2>
		 		<h6>database</h6>
		 	</div>
		 </a>
	</div>
</div>
<div class="wrapper">
	<div class="container launch-block pad-space">
		<h2>Launching soon<span><sup>OncoPept<i>TCR<sup> TM</sup></i></sup></span>
		and<span><sup>OncoPept<i>COMBI <sup> TM<sup></i></sup></span></h2>
		<div class="col-xs-9">
			<h4>OncoPept<i>TCR <sup>TM</sup></i></h4>
		</div>
		<div class="col-xs-15">
			<p>- NGS based TCR repertoire analysis for 
			differential   diagnosis of T-cell related pathology</p>
		</div>
		<div class="col-xs-9">
			<h4 class="p-t20">OncoPept<i>COMBI<sup> TM </sup></i></h4>
		</div>
		<div class="col-xs-15">
			<p class="p-t20">- Provides molecular rational to combine therapies
			 developed in the immuno-oncology space
			</p>
		</div>
	</div>
</div>
<div class="wrapper">
	<div class="container Note-block">
		<p>MedGenome Inc. is a genomics-based research company 
		headquartered in California with the mission to improve global health 
		by decoding genetic information contained in an individual's genome. 
		It is also a founding member of GenomeAsia 100K initiative to sequence
		100,000 Genomes in South, North and East Asia. Our NGS lab in Foster City,
		 California is ISO 15189 compliant, CLIA certified, and CAP accredited.</p>
	</div>
</div>
<div class="wrapper">
	<div class="container social-block">
		<h2>Letâ€™s fight cancer together</h2>
		<h6><a href="mailto:hiranjith.gh@medgenome.com">hiranjith.gh@medgenome.com </a>|<span> (888) 440-0954 ; Ext-102</span></h6>
		<div >
			<span class="facebook"></span>
			<span class="twitter"></span>
			<span class="in"></span>
		</div>
	</div>
</div>

<div class="top-arrow hide hidden-xs" id="scroll-top">
	<div class="fa fa-arrow-up"></div>
</div>
<?php require 'php-templates/footer.php' ?>